Press Releases Novo Nordisk A/S

Stocks

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2026-07-17 EDT			5-day change	1st Jan Change
329.90 ^DKK	-1.76%		+2.37%	+1.43%

07-17	Abbott investigates two separate cyber incidents, says no operations affected	RE
07-17	Novo Nordisk to launch lower-cost Ozempic copy in South Africa	RE

Press Releases

07-15	Novo Nordisk receives European Commission approval of Wegovy® pill as first oral GLP-1 for weight management in the EU; single, ready-to-use pen for higher dose 7.2 mg also approved	GL
07-15	Fake Weight-Loss Medications And New Enforcement Possibilities	AQ
07-14	Courts Deploy Dynamic Blocking Order To Combat Counterfeit Medicines	AQ
07-13	Novo Nordisk A/S - share repurchase programme	GL
07-09	OPEN Ears Episode 21 Is Out!	AQ
07-07	Ozempic(R) Savings Card Program Expanded for Patients with Private Coverage	AQ
07-06	Novo Nordisk A/S - share repurchase programme	GL
06-30	Canada approves generic version of Wegovy for weight loss	AQ
06-29	Canada approves first generic semaglutide injection for weight loss	AQ
06-29	Novo Nordisk A/S - share repurchase programme	GL
06-23	Ozempic's Unintended Uses	AQ
06-22	Novo Nordisk A/S - share repurchase programme	GL
06-15	Novo Nordisk A/S - share repurchase programme	GL
06-11	Novo Nordisk A/S: IT Security incident at Novo Nordisk	GL
06-11	Novo Nordisk A/S: IT Security incident at Novo Nordisk	AQ
06-11	Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK	GL
06-11	Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK	AQ
06-11	The Secret Behind The Success Of WeGovy - Inside Novo Nordisk (Podcast)	AQ
06-09	Novo Nordisk focuses on longevity and aesthetic medicine, going beyond weight loss	AQ
06-08	Novo Nordisk A/S - share repurchase programme	GL
06-03	Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care	GL
06-02	Parker Waichman LLP Files Lawsuit on behalf of Pennsylvania Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy	AQ
06-01	Novo Nordisk A/S - share repurchase programme	GL
05-26	Novo Nordisk A/S - share repurchase programme	GL
05-26	Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke	GL